INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
The need for further improvement of treatments for Takayasu’s arteritis (TA), the progress in understanding the mechanisms of the disease, and the introduction of biological agents (BA) in rheumatology practice have created preconditions for developing a new TA pharmacotherapy using BA associated wi...
Main Authors: | T. V. Beketova, E. L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2017-10-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2437 |
Similar Items
-
The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
by: V. N. Antipova, et al.
Published: (2021-01-01) -
Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
by: G. M. Koilubaeva, et al.
Published: (2022-05-01) -
A Case Report of Takayasu’s Arteritis
by: O.O. Andrushkova, et al.
Published: (2017-04-01) -
Intracranial Involvement in Takayasu’s Arteritis
by: Andrea Johnson, et al.
Published: (2021-10-01) -
Takayasu’s Arteritis: A Special Case Report and Review of the Literature
by: Paloma Moisii, et al.
Published: (2024-03-01)